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Abstract 
Background: This is an update to our 2012 publication on clinical trial considerations on male contraception and 
collection of pregnancy information from female partner, after critical review of recent (draft) guidances released by 
the International Council for Harmonisation [ICH] the Clinical Trial Facilitation Group [CTFG] and the US Food & Drug 
Administration [FDA].
Methods: Relevant aspects of the new guidance documents are discussed in the context of male contraception and 
pregnancy reporting from female partner in clinical trials and the approach is updated accordingly.
Results: Genotoxicity The concept of a threshold is introduced using acceptable daily intake/permissible daily 
exposure to define genotoxicity requirements, hence highly effective contraception in order to avoid conception. The 
duration for highly effective contraception has been extended from 74 to 90 days from the end of relevant systemic 
exposure. Teratogenicity Pharmacokinetic considerations to estimate safety margins have been contextualized with 
regard to over- and underestimation of the risk of teratogenicity transmitted by a vaginal dose. The duration of male 
contraception after the last dose takes into account the end of relevant systemic exposure if measured, or a default 
period of five half-lives after last dose for small molecules and two half-lives for immunoglobulins (mAbs). Measures 
to prevent exposure of the conceptus via a vaginal dose apply to reproductively competent or vasectomized men, 
unless measurements fail to detect the compound in seminal fluid.
Conclusion: Critical review of new guidance documents provides a comparison across approaches and resulted 
in an update of our previous publication. Separate algorithms for small molecules and monoclonal antibodies are 
proposed to guide the recommendations for contraception for male trial participants and pregnancy reporting from 
female partners. No male contraception is required if the dose is below a defined threshold for genotoxic concern 
applicable to small molecules. For men treated with teratogenic mAbs, condom use to prevent exposure of a poten-
tially pregnant partner is unlikely to be recommended because of the minimal female exposure anticipated following 
a vaginal dose. The proposed safety margins for teratogenicity may evolve with further knowledge.
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Background
In 2012, we proposed an approach to consistently assess 
need for contraception for men exposed in clinical trials 
to genotoxic and/or teratogenic compounds or to com-
pounds of unknown teratogenicity, and to collection of 
pregnancy data from their female partner [1]. The cur-
rent update was triggered by three guidance documents 
which became available since 2014, namely, the Interna-
tional Council for Harmonisation (ICH) guideline M7 on 
mutagenic impurities in drugs [2], the guidance from the 
Clinical Trial Facilitation Group (CTFG) on recommen-
dations related to contraception and pregnancy testing in 
clinical trials [3] and the draft guidance for industry from 
the US Food and Drug Administration (FDA) regard-
ing assessment of male-mediated developmental risk for 
pharmaceuticals [4].
Methods
Relevant aspects of the new guidance documents are 
summarized and the approach to male contraception in 
clinical trials has been updated accordingly.
Results and discussion
Review of relevant aspects from guidance documents
ICH M7: assessment and control of DNA reactive (mutagenic) 
impurities in pharmaceuticals to limit potential carcinogenic 
risk [2]
Mutations in germ cells can lead to spontaneous abor-
tions, infertility or heritable damage to the offspring and 
possibly to the subsequent generations [5]. As stated 
by ICH S2 (R1) [6], “most germ cell mutagens are likely 
to be detected as genotoxic in somatic cell tests so that 
negative results of in vivo somatic cell genotoxicity tests 
generally indicate the absence of germ cell effects”. Thus, 
standard genotoxicity assays performed in somatic cells 
in vitro and in vivo are appropriate to assess the risk of 
potential genetic damage of germ cells.
For genotoxicity, the term threshold is used in two dif-
ferent types of data contexts: (a) to describe non-linear 
thresholded dose–effect relationships for genotoxic com-
pounds, which mostly interact indirectly with the genetic 
material; (b) to describe a Threshold of Toxicological 
Concern (TTC) below which even for a linear dose–
effect relationship, the predicted risk is so low that fur-
ther risk minimization efforts are not warranted.
Non-linear dose–responses suggest that a threshold 
dose is required in order to induce an adverse effect. 
Non-linear dose–responses have been reported for 
low doses of genotoxic compounds with diverse indi-
rect (e.g. aneugens, topoisomerase inhibitors etc.) and 
direct deoxyribonucleic acid (DNA) reactive mecha-
nisms (e.g. alkylating agents) and the shape of the respec-
tive dose–response appears to be dependent on related 
cytoprotective cellular processes. It is however unlikely 
that small genotoxic effects, i.e. within the normal back-
ground range, can be excluded experimentally. Thus, 
published data mostly report practical thresholds where 
non-linear dose–responses are described through sta-
tistical approaches to define a point of departure. The 
least complex are the single effect levels such as the no 
observed genotoxic effect level (NOGEL) and the low-
est observed genotoxic effect level (LOGEL). The regula-
tory approach to such compounds can be based on the 
identification of a NOGEL and use of uncertainty factors 
to calculate a permissible daily exposure when data are 
available.
For the majority of direct DNA genotoxins there is 
no experimental evidence of a threshold relative to a 
genotoxic effect–dose (concentration) curve. In these 
instances, the dose (concentration)- response curve is 
linear (i.e. non-thresholded) and the concept of TTC may 
be applied for risk assessment.
The TTC has originally been allocated for mutagenic 
impurities in drug formulations at a calculated risk 
level of one additional cancer case in 100,000 exposed 
patients for a lifetime intake. The TTC concept was 
developed to define an acceptable daily intake for any 
unstudied chemical that poses a negligible risk of car-
cinogenicity or other toxic effects. The TTC-based 
acceptable intake of 1.5  μg/day is considered to be 
protective for a lifetime of daily exposure. To address 
less-than-lifetime exposure to mutagenic impuri-
ties in pharmaceuticals, an approach is applied in 
which the acceptable cumulative lifetime dose (1.5  μg/
day × 25,550 days = 38.3 mg) is uniformly distributed 
over the total number of exposure days during less-
than-lifetime exposure. This would allow a higher daily 
intake than would be the case for lifetime exposure 
and still maintain comparable risk levels for daily and 
non-daily treatment regimens. However, a uniform dis-
tribution ignores experimental data, which have demon-
strated a higher risk for cancer mediated by mutations if 
the same cumulative dose is taken over a shorter than 
a longer duration. Hence, less-than-lifetime exposure 
values for shorter than lifetime exposure situations have 
incorporated additional safety margins to account for 
this experimental observation (Table 1).
Clinical trial facilitation group (CTFG): recommendations 
related to contraception and pregnancy testing in clinical 
trials [3]
The CTFG supports the Heads of Medicines Agencies, a 
network of the heads of the National Competent Author-
ities whose organizations are responsible for the regula-
tion of medicinal products for human and veterinary use 
in the European Economic Area.
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The CTFG guidance document includes the following 
definitions:
  • Highly effective and acceptable contraceptive meas-
ures and categorization of contraceptives
  • End of relevant systemic exposure: Time point where 
the Investigational Medicinal Product including any 
active or major metabolites, has decreased to a con-
centration that is no longer considered relevant for 
human teratogenicity/fetotoxicity
  • Duration of one sperm cycle: The duration of a sperm 
cycle is defined as 90 days
  • Menopause: A postmenopausal state is defined as no 
menses for 12 months without an alternative medical 
cause. A high follicle stimulating hormone (FSH) level 
in the postmenopausal range may be used to confirm 
a postmenopausal state in women not using hormo-
nal contraception or hormonal replacement therapy. 
However in the absence of 12 months of amenorrhea, 
a single FSH measurement is insufficient.
The key messages of the CTFG guidance paper con-
cerning contraception in context of exposed men in clini-
cal trials are listed below.
  • In case of a genotoxic Investigational Medicinal 
Product, the principle of TTC as available for muta-
genic impurities should be considered.
  • The following three main risk categories for the early 
stages of pregnancy have been adapted from the 
risk categories set in the Committee for Medicinal 
Products for Human Use (CHMP) guideline EMEA/
CHMP/203927/2005 [7]:
Demonstrated or suspected human teratogenicity/
fetotoxicity in early pregnancy
Possible human teratogenicity/fetotoxicity in early 
pregnancy
Unlikely human teratogenicity/fetotoxicity in early 
pregnancy
  • Referring to Klemmt and Scialli [8], CTFG assumes 
the estimated drug exposure level in the female part-
ner of child-bearing potential after a vaginal dose to 
be three or more orders of magnitude lower than the 
plasma concentration in the male clinical trial partic-
ipant [3]. Subsequently, CTFG concludes that the risk 
of teratogenicity from a vaginal dose only applies to 
those drugs with demonstrated or suspected human 
teratogenicity/fetotoxicity at sub-therapeutic sys-
temic exposure levels and not to drugs with (dem-
onstrated or suspected) teratogenicity at therapeutic 
or supratherapeutic levels. However, sub-therapeutic 
systemic exposure level is not further described and 
quantified.
  • In cases where reproductive toxicity studies are avail-
able, the anticipated systemic exposure in trial par-
ticipants should have a sufficient exposure margin 
below the no adverse effect level (NOAEL) in the 
non-clinical embryo-fetal development (EFD) stud-
ies; otherwise, condom use is required. However, a 
margin is not quantified.
  • In case of insufficient or unavailable non-clinical 
data, the impact on the risk categorization should be 
evaluated. “Unavailable or insufficient non-clinical 
data”, should be considered as “effects detected”, and 
the highest possible risk category assumed.
  • In the absence of EFD studies, end of relevant sys-
temic exposure may be based on the principles of 
a Minimum Anticipated Biological Effect Level 
(MABEL) or other accepted principles.
FDA draft guidance for industry: assessment 
of male‑mediated developmental risk for pharmaceuticals [4]
The FDA draft guidance for industry was distributed for 
comments in June 2015. It provides recommendations 
to sponsors for assessing risks to embryo-fetal develop-
ment resulting from administration of an active pharma-
ceutical ingredient to males, either through an effect on 
the male germ cell or from seminal transfer of an active 
pharmaceutical ingredient that has been shown to be 
genotoxic or a potent developmental toxicant. A potent 
developmental toxicant is defined as one associated with 
adverse fetal outcomes at or near clinical exposures or for 
which a NOAEL has not been defined.
The guidance does not consider the situation where no 
EFD studies were performed and does not specify safety 
margins. Examples are provided with estimated expo-
sure multiples of 50- fold and 20-fold between Cmax in 
female partners and Cmax associated with NOAEL in EFD 
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studies with the conclusion that no further assessment of 
the drug in seminal fluid would be needed. Examples for 
no NOAEL from EFD studies are not provided.
Risk assessment considerations
Risk assessment for genotoxicity
The impact of positive genotoxicity findings on the devel-
opment of a small molecule depends on the indication, 
the patient population and the duration of treatment. 
Genotoxic compounds are generally not tested in healthy 
volunteers and if so, require an extensive risk assessment. 
According to literature, in general, single-dose clinical 
studies are permitted by the FDA regardless of the gen-
otoxicity test results [9]. However, some other Health 
Authorities may not agree to test genotoxic compounds 
with single doses in healthy volunteers or may request a 
rationale to do so and safety margins have been accepted 
on a case-by-case basis.
The existence of mechanisms leading to a dose response 
that is non-linear and has a practical threshold is increas-
ingly recognized, not only for compounds that interact 
with non-DNA targets but also for DNA-reactive com-
pounds [10]. Those effects may be modulated, for exam-
ple, by rapid detoxification before coming into contact 
with DNA, or by effective repair of induced DNA lesions. 
Direct DNA interactions may result in the formation of 
small or bulky adducts, DNA strand cross-links, DNA–
protein cross-links and DNA strand breaks. Indirect 
mechanisms can be related to the inhibition of DNA 
repair, impairment of chromosome segregation, disrup-
tion of mitotic checkpoints machinery, inhibition of apop-
tosis, perturbation of cytokinesis, inhibition of enzymes 
involved in the maintenance of DNA methylation, and 
induction of inflammation and/or mitochondrial dysfunc-
tion leading to increased oxidative stress [11].
For drugs with an indirect (non-DNA) genotoxic 
mechanism, a non-linear genotoxic effect to dose (con-
centration) curve is typical, allowing the identification of 
a NOGEL. Based on the integrated data, the genotoxic 
risk and the safety margin need to be assessed, including 
the cut-off concentration or permissible daily exposure in 
the female partner below which the predicted genotoxic 
risk is low, hence, for which highly effective contracep-
tion including condom use is not needed.
Also for some molecules with a direct genotoxic mech-
anism, a non-linear dose genotoxic response with a range 
of non-mutagenic low concentrations and a NOGEL has 
been found in vitro, as it is typically seen for molecules 
with an indirect mode of genotoxicity [12, 13]. This is 
likely based on specific DNA lesions and their removal 
by DNA repair enzymes in an error-free fashion. This 
process cannot be generalized and for the majority of 
direct DNA genotoxins there is no experimental evidence 
of a threshold relative to a genotoxic effect–dose (con-
centration) curve. In these instances, the dose (concen-
tration) response curve is linear (i.e. non-thresholded) 
and the concept of TTC as defined for impurities in ICH 
M7 [2] may be applied for risk assessment.
Implications of guidance documents on the 2012 
genotoxicity approach
In comparison to the 2012 publication [1], the concept of a 
threshold in line with ICH M7 is introduced using accept-
able daily intake or permissible daily exposure to define 
genotoxicity requirements. However, application of the 
TTC concept with acceptable daily intake, adopted from 
CTFG, very likely results in recommending highly effec-
tive contraception based on the very low acceptable daily 
intake. For methods of highly effective contraception, ref-
erence is made to the CTFG guidance document as rec-
ommended by MHRA. The MHRA Medical Guidance on 
“Clarification of contraceptive wording in clinical trials”, 
2009 is superseded. Also, the duration of highly effective 
contraception has been extended from 74 to 90 days from 
the end of relevant systemic exposure as suggested by the 
CTFG guidance document. Finally, a reference has been 
added supporting testing of single doses in clinical trials 
in the US, regardless of genotoxicity test results.
Risk assessment for teratogenicity
Pharmacokinetics (PK) considerations
Scenario 1: A NOAEL from EFD studies in animals is 
available
Preclinical reference parameters In this scenario the pre-
clinical pharmacokinetic reference parameter taken for 
safety margin calculations is the Area Under the Curve 
(AUC) associated with the NOAEL from the more sensi-
tive animal species.
Clinical reference parameters/estimating the exposure 
in the female partner after a vaginal dose The AUC esti-
mated for the female parameter following a vaginal dose 
is used as reference for comparison against the AUC 
associated with the NOAEL from EFD animal studies.
Indeed, drug induced teratogenicity in animals has 
been found to be associated with maximum concentra-
tion (Cmax) or AUC [14]. Because the ratio of Cmax/AUC 
in small animals as used in EFD studies is typically higher 
than in man, using AUC instead of using Cmax as the rel-
evant PK parameter provides a smaller margin between 
exposure in animals and the estimated exposure in female 
Page 5 of 14Banholzer et al. Clin Trans Med  (2016) 5:23 
partner. In consequence, calculating safety margins based 
on AUC represents the more conservative approach 
compared to safety margins calculated with Cmax.
Small molecules: The dose-exposure relationship for 
plasma concentrations is assumed to be similar for the 
female partner and the exposed male. Exposure param-
eters, here AUC, in the female partner are extrapolated 
for the vaginal dose from available clinical PK data or PK 
modeling assuming linear PK.
The vaginal dose is derived from multiplying the semi-
nal concentration with the volume of seminal fluid (6 mL 
corresponds to the 90 percentile for seminal volume 
[15]). The seminal concentration is assumed to equal the 
plasma concentration in the exposed male. The extent of 
vaginal absorption and the placental transfer relative to 
female exposure are assumed to be 100 % each.
Monoclonal antibodies (mAbs): For mAbs, the calcula-
tion of the vaginal dose assumes a seminal concentration 
of 1  % of the plasma concentration because this is the 
ratio commonly reported for IgGs [16–18]. In a recent 
publication on an IgG2, a 2  % ratio for seminal fluid/
plasma concentration was measured [19]. The extent of 
vaginal absorption is assumed as 10 % given the limited 
information available [20, 21]. However, a recent publi-
cation in Cynomolgus monkeys shows an extent of IgG 
vaginal absorption well below 1 % [22, 23].
A dilution factor of 500 is used on the basis that the 
seminal fluid volume is 6 mL and the plasma volume is 
about 3000 mL which typically represents the volume of 
distribution of the mAb. Overall, this estimate results in 
the assumption that the concentrations of mAbs in the 
plasma of the female partner is ~500,000-times lower 
than in the exposed male trial participant:   ×100 (1  % 
seminal concentration relative to plasma concentra-
tion in exposed male) ×10 (10 % due to vaginal absorp-
tion)  ×500 (dilution of 6  mL seminal fluid in plasma 
volume of 3000 mL).
Scenario 2: No NOAEL from EFD studies in animals 
has been established or no EFD studies are available
Preclinical reference parameters In this scenario, the 
MABEL derived from an AUC in animal studies or repre-
senting a concentration resulting from a cellular experi-
ment may be considered.
Clinical reference parameters In case the MABEL repre-
sents an in  vitro concentration, the estimated Cmax for 
the female partner after a vaginal dose should be used. 
In case the MABEL relates to an animal experiment, we 
propose to compare the associated AUC with the esti-
mated AUC in the female partner. Please note, the use 
of AUC was not specified in the 2012 publication. The 
approach for estimating the exposure in female partner is 
outlined for scenario 1.
The MABEL approach should consider additional 
points:
  • No off-target effect including (major) metabolites.
  • A MABEL assessment in an in vitro setting may refer 
to a target outside the plasma compartment, e.g. the 
brain. PK considerations should then translate the 
MABEL concentration to the associated predicted 
concentrations in the plasma compartment. Margin 
calculations use the estimated female exposure, here 
Cmax, and the relevant plasma concentration corre-
sponding to the MABEL.
  • No toxicities linked to pharmaceutical properties 
(e.g. drug deposition in bradytrophic tissues such as 
bone, cartilage, lens).
  • The MABEL derived exposures are lower than the 
lowest exposure tested in EFD studies.
First pass effects and underestimation of exposure to 
female partner and embryo/fetus
The mode of estimating the exposure in the female part-
ner after a vaginal dose may result in underestimation of 
the exposure in the female partner and in the embryo/
fetus. For small molecules administered vaginally this 
may include the absence of intestinal-hepatic first pass 
effect and the presence of uterine first pass effect. The lat-
ter may also be applicable for mAbs. In case an estimate 
for a first pass effect is available, the safety margin may be 
individualized.
Intestinal-hepatic first pass effect The extrapolation from 
vaginal dose to exposure in female partner refers to avail-
able PK information. If this PK information is derived 
from PK after oral administration and if the molecule 
undergoes relevant first pass effect by intestine and liver, 
the estimated female exposure after vaginal dose will 
underestimate the true exposure because of the absence 
of first pass intestine and hepatic effects after the vagi-
nal route of administration. The absence of the intesti-
nal-hepatic first pass effect after a vaginal dose may be 
corrected by multiplying the derived estimated AUC/
Cmax values from oral administration with [1 ÷ (1 − first 
pass effect)].
Uterine first pass effect The uterine first pass effect 
describes the extraction of drug by the uterus following 
the countercurrent transfer of a molecule after vaginal 
absorption via vaginal vein drainage to uterine arter-
ies. When measured in non-pregnant subjects or in 
perfused hysterectomy, the ratio of drug concentration 
in endometrium or uterine artery versus systemic vein 
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concentration is about two to sevenfold higher after 
vaginal than after systemic drug administration based on 
reports for progesterone [24], danazol [25], thalidomide 
[26].
Safety margin considerations
Regulatory guidelines lack recommendations regarding 
safety margins for teratogenicity between NOAEL in EFD 
studies a and maximum doses tested in clinical trials. 
For first-in-human studies applying a range of escalat-
ing doses, the FDA suggests a default safety factor of ten 
between the exposure for the starting dose and that of the 
Human Equivalent Dose, which should be individualized 
[27]. In our experience, for non-monitorable and poten-
tially irreversible and severe toxicities, a safety factor of 
ten is usually applied between exposure associated with 
the maximum dose in a clinical trial and the NOAEL in 
EFD studies. Given the uncertainties around predicting 
exposure in the female partner/fetus and the potential 
serious outcome in the development of the embryo-fetus, 
a safety margin higher than tenfold is proposed between 
NOAEL in EFD studies and exposures associated with 
the maximum dose in the clinical trial. Of note, the FDA 
draft guidance states that a margin of at least tenfold 
between NOAEL in EFD studies and the estimated expo-
sure to embryo-fetus due to vaginal dose would not man-
date evaluation of drug in seminal fluid.
Scenario 1: safety margins proposed when a NOAEL 
from EFD studies in animals is available
When a NOAEL and its associated AUC from non-clin-
ical EFD studies is available, a margin of at least 300 is 
requested relative to the expected exposure (AUC) in the 
female partner for small molecules and of at least 100 for 
mAbs. The smaller margin for mAbs appears justified 
because the exposure in the female partner is more pre-
dictable than for small molecules, given the more gener-
alizable PK of mAbs. If the seminal concentration for a 
small molecule is not estimated, but has been measured, 
we propose to reduce the required safety margin from 
300 to 100.
Scenario 2: safety margins proposed when no NOAEL 
Has been established in EFD studies or no EFD stud-
ies are available
When a NOAEL has not been established or no EFD 
studies have been conducted, male contraception is pro-
posed unless there is a sufficient margin between the 
estimated exposure of female partner and the MABEL of 
the molecule.
Margin calculations using MABEL refer to the dis-
tinction between teratogenicity at therapeutic and 
sub-therapeutic levels as made in the CTFG paper. For 
a Hill coefficient e.g. of 1, a 81-fold increase in con-
centration is needed to increase a response from 10 
(assumed level for MABEL) to 90  % (assumed thera-
peutic level) [28]. In the safety margin considera-
tions below, a factor of 100 instead of 81 is considered 
between MABEL, taken as sub-therapeutic level, and 
therapeutic level.
For small molecules, the safety margins as defined for 
EFD studies with NOAEL apply, i.e. 300 when the semi-
nal concentration is estimated and 100 if the seminal 
concentration is measured.
For mAbs, the safety margin from EFD studies with 
NOAEL is lowered from 100 to 10 with the MABEL 
approach to account for the limited placental transfer of 
about 10  % during the most vulnerable organogenesis 
phase, i.e. the first trimester.
The safety margin estimations supporting contracep-
tive recommendations are summarized in Fig. 1 for small 
molecules and in Fig. 2 for mAbs.
Differences in PK and safety margin considerations 
between our approach and the FDA draft guidance
Comparison is done to the draft FDA guidance since the 
CTFG guidance does not include details about PK.
Factors used to estimate the exposure in the female 
partner after a vaginal dose for small molecules and 
mAbs are displayed in Table 2 which includes a compari-
son with the FDA draft guidance.
To calculate the vaginal dose, the FDA draft guidance 
uses a seminal fluid volume of 5  mL instead of 6  mL 
(6 mL corresponds to the 90 percentile for seminal vol-
ume [15]).
For mAbs, the FDA approach estimates Cmax in female 
partner as vaginal dose absorbed divided by blood vol-
ume instead of plasma volume. Consequently, the dilu-
tion factor to estimate female exposure from vaginal dose 
is half in our approach compared with the one suggested 
in the FDA draft guidance. Because the PK derived from 
animals typically refers to measurements of mAbs in 
plasma, it is therefore important to ensure that exposure 
comparisons between species apply the same matrix and 
compartment.
For small molecules, the FDA approach estimates the 
female Cmax as vaginal dose divided by blood volume 
Page 7 of 14Banholzer et al. Clin Trans Med  (2016) 5:23 
which corresponds to Cmax after rapid iv injection. Given 
the delayed time to maximum plasma concentration after 
vaginal administration this overestimates Cmax. Indeed, 
PK data for drugs administered vaginally show that the 
time to maximum plasma concentration is not instant 
as per IV administration but takes several hours, e.g. for 
Scenario 1:
No NOAEL in EFD –>
MABEL
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Fig. 1 Safety margin estimations: small molecules. AUC area under the curve, Cmax maximum concentration, Cplasma plasma concentration, Csemen 
seminal concentration, EFD embryo-fetal development, MABEL minimum anticipated biological effect level, NOAEL no adverse effect level
Page 8 of 14Banholzer et al. Clin Trans Med  (2016) 5:23 
Scenario 1:
No NOAEL in EFD –>
MABEL
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Fig. 2 Safety margin estimations: monoclonal antibodies. AUC area under the curve, Cmax maximum concentration, Csemen seminal concentration, 
EFD embryo-fetal development, mAb monoclonal antibody, MABEL minimum anticipated biological effect level, NOAEL no adverse effect level
metronidazole [29], clindamycin [30] and progesterone 
[24]. It is acknowledged that the vaginal absorption rate 
is dependent on the physico-chemical properties of the 
molecule, the formulation used, and the vaginal epithe-
lium status. The Cmax in female partners is influenced 
by the volume of distribution, which varies across small 
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molecules. Consequently, Cmax is likely lower compared 
to the estimate as suggested in the FDA draft guidance.
In our approach, the presence of an intestinal-hepatic 
first pass effect, when using oral PK data to extrapolate 
from vaginal dose to female systemic exposure, results 
in an underestimation of exposure to female partner 
and embryo/fetus. As stated previously, in case an esti-
mate for a first pass effect is available, the safety margin 
may be individualized. The FDA approach is not associ-
ated with such an underestimation because this approach 
does not refer to available PK data after oral administra-
tion when estimating female exposure after vaginal route 
of administration.
On the other hand and as outlined earlier, using AUC 
rather than Cmax to compare NOAEL in animals with 
estimated female exposure represents the more conserv-
ative selection of PK parameter.
Implications of guidance documents on the 2012 
teratogenicity approach
The CTFG makes reference to sub-therapeutic and thera-
peutic levels for assessing the need for contraception. 
Furthermore, the guidance suggests the MABEL concept 
as a preclinical reference parameter in  situations where 
no EFD studies are available to define the end of relevant 
systemic exposure. In our 2012 publication, the use of 
MABEL has been suggested in the case no EFD stud-
ies are available or no NOAEL could be established in 
EFD studies in order to estimate safety margins whereby 
MABEL is considered to be a sub-therapeutic level. The 
examples provided in the FDA draft guidance do not 
include MABEL or a scenario with no NOAEL in EFD 
studies. The MABEL recommendation as specified in our 
2012 publication remains unchanged.
The FDA draft guidance as well as our approach sug-
gest that condom use is recommended in case a tera-
togenic risk remains unknown/uncertain or in case a 
risk of male-mediated developmental toxicity has been 
determined to exist. In the CTFG guidance document, 
the contraception recommendations also apply for risk 
unknown. However, condom use for embryo-fetal risk 
from treatment of male subjects with investigational 
medicinal products only applies to investigational medic-
inal products with demonstrated or suspected human 
teratogenicity/fetotoxicity in early pregnancy at sub-ther-
apeutic systemic exposure levels (not further specified). 
The recommendation for condom use in case of terato-
genicity remains unchanged.
The FDA draft guidance emphasizes the need for condom 
use also for vasectomized men unless measurements using 
an adequate assay fail to detect the molecule in seminal 
fluid. This consideration has been added to our approach.
Contraceptive needs
Contraceptive needs relative to genotoxicity testing outcome
With genotoxic small molecules, the aim is to avoid 
conception until the end of relevant systemic exposure 
plus 90 days. Men with a female partner of childbearing 
potential should use condoms plus an additional contra-
ceptive method that together result in a failure rate of 
<1 % per year if the criteria below are met:
  • The small molecule has been found to be genotoxic 
in non-clinical studies or genotoxicity testing has not 
been completed
  • The clinical dose is >permissible daily exposure/
acceptable daily intake based on NOGEL for com-
pounds with a thresholded non-linear dose–response 
relationship or based on TTC for compounds with a 
linear dose–response relationship, respectively.
Duration of contraceptive measures
The contraceptive measures should be maintained during 
treatment and until the end of relevant systemic exposure 
plus 90 days (i.e. 60–75 days for sperm production plus 
10–14 days for the transport to the epididymis). In gen-
eral, the end of relevant systemic exposure for small mol-
ecules may be defined, by default, as five half-lives after 
the last dose.
Contraceptive needs relative to teratogenicity testing 
outcome
With teratogenic compounds, the aim is to avoid expo-
sure of the conceptus via a vaginal dose until the end of 
relevant systemic exposure.
Small molecules
Condom use in men with a pregnant partner or a partner 
of child-bearing potential (i.e. unknown early pregnancy 
status) is required under the following circumstances:
Scenario 1: NOAEL from EFD studies is available
a. Female AUC extrapolated from the vaginal 
dose (male Cmax  ×  6  mL of semen)  >  (NOAEL 
AUC) ÷ 300 (if seminal concentration is estimated) 
or
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b. Female AUC extrapolated from the vaginal 
dose (male Cmax  ×  6  mL of semen)  >  (NOAEL 
AUC)  ÷  100 (if seminal concentration has been 
measured)
Scenario 2: EFD or NOAEL from EFD studies is not 
available
a. Female Cmax or AUC extrapolated from vaginal dose 
(male Cmax × 6 mL of semen) > (MABEL concentra-
tion or AUC) ÷ 300 (if seminal concentration is esti-
mated) or
b. Female Cmax or AUC extrapolated from vaginal dose 
(male Cmax × 6 mL of semen) > (MABEL concentra-
tion or AUC)  ÷  100 (if seminal concentration has 
been measured) or
c. Female Cmax or AUC extrapolated from vaginal dose 
(male Cmax × 6 mL of semen) > (therapeutic concen-
tration or AUC; in case Hill coefficient is 1) ÷ 30,000 
(if seminal concentration is estimated) or
d. Female Cmax or AUC extrapolated from vaginal dose 
(male Cmax × 6 mL of semen) > (therapeutic concen-
tration or AUC; in case Hill coefficient is 1) ÷ 10,000 
(if seminal concentration has been measured)
Monoclonal antibodies
Condom use in men with a pregnant partner or a partner 
of child-bearing potential (i.e. unknown early pregnancy 
status), is required under the following circumstances:
Scenario 1: A NOAEL from EFD studies is available
a. Male AUC > (NOAEL AUC) × 5000
Scenario 2: NOAEL from EFD studies is not available
a. Male Cmax or AUC  >  (MABEL concentration or 
AUC) × 50,000
b. Male Cmax or AUC  >  (therapeutic concentration or 
AUC) × 500
Duration of condom use
Condom use is required during treatment and until the 
end of relevant systemic exposure, which may be defined 
by default, as five half-lives after the last dose for small 
molecules and two half-lives after the last dose for mAbs.
Combined algorithms for genotoxicity and teratogenicity
Figures  3 and 4 show algorithms combining genotoxic-
ity and teratogenicity for small molecules and for mAbs, 
respectively.
Conclusions
Relevant aspects of new guidance documents were taken 
into account in updating our approach to male contra-
ception requirements in clinical trials.
For genotoxicity, a threshold concept based on ICH M7 
and in line with CTFG, was introduced using permissi-
ble daily exposure/acceptable daily intake to define the 
requirement for highly effective contraception related to 
small molecules. The use of acceptable daily intake based 
on a TTC is unlikely to result in a waiver for highly effec-
tive contraception because the clinical daily dose of a 
molecule to be tested must be very low (e.g. up to 120 µg 
per day for a treatment period up to 1 month). Hence, the 
impact of using a TTC on the 2012 contraception recom-
mendations is considered low.
For men treated with teratogenic mAbs, condom use 
to prevent exposure of a potentially pregnant partner 
is unlikely to be recommended because of the minimal 
female exposure anticipated following a vaginal dose.
Pharmacokinetic considerations for estimating expo-
sure in female partners after vaginal dose are compared 
across the CTFG guidance document, the FDA draft 
guidance, and our approach. In particular with regard 
to the potential for over- or underestimation of the 
exposure in female partners and embryo-fetus. Outline 
of these aspects contributes to the proposal for safety 
margins and potential individualization relative to PK 
characteristics. The proposed safety margins for terato-
genicity may evolve with further knowledge and inter-
actions with Health Authorities. Finally, new methods 
of contraception may become available over time.
Since female partners do not participate in the clinical 
trial and have not given their consent, it is the responsi-
bility of the man exposed to a study drug to inform his 
female partner of the need to comply with the risk mini-
mization measures. Pregnancy data should be proac-
tively collected for females becoming pregnant as partner 
of men given genotoxic small molecules. Similarly, data 
should be collected if the female partner becomes preg-
nant during the period condom use is required for men 
exposed to molecules which are first-in-class or with a 
target/class shown to be teratogenic, embryotoxic or 
fetotoxic in human or in preclinical experiments. Recom-
mendations for collection of pregnancy information from 
female partners of exposed men are unchanged com-
pared to our 2012 publication.
This work represents the view of the authors based on 
current knowledge after consideration of new aspects rel-
evant to assess the potential genotoxic and/or teratogenic 
risk via a seminal dose.
Page 12 of 14Banholzer et al. Clin Trans Med  (2016) 5:23 
Clinical dose is > PDE/ADI Clinical dose is ≤ PDE/ADI
Use of a condom plus an addional contracepve method that 
together result in a failure rate of <1% per year to avoid concepon 
during treatment and unl the end of relevant systemic exposure in 
the exposed male or for 5 terminal half-lives PLUS 90 day  (life span of 
spermatozoa of 60-75 days for sperm producon + 10-14 days for 
transport to epididymis). Furthermore, exposed men should agree to 
refrain from donang sperm. 
Posive Genotoxicity Tesng
 1. No EFD studies available OR no EFD NOAEL: 
Female Cmax/AUC extrapolated from vaginal dose (male Cmax/AUC x 
6 mL of semen) is any of the following:
> MABEL Concentraon/AUC ÷ 300 or > Therapeuc 
concentraon/AUC ÷ 30'000 (if seminal concentraon is 
esmated) 
> MABEL Concentraon/AUC ÷ 100 or > Therapeuc 
concentraon/AUC ÷ 10'000 (if seminal concentraon is 
measured)
2. EFD NOAEL available: 
Female AUC extrapolated from vaginal dose (male Cmax x 6 mL of 
semen) is any of the following:
> NOAEL-AUC ÷ 300 (if seminal concentraon is esmated)
> NOAEL-AUC ÷ 100 (If seminal concentraon is measured) 
1. No EFD studies available OR no EFD NOAEL: 
Female Cmax/AUC extrapolated from vaginal dose 
(male Cmax/AUC x 6 mL of semen) is any of the following:
≤ MABEL Concentraon/AUC ÷ 300 or < Therapeuc 
concentraon/AUC  ÷ 30'000 (if seminal concentraon is 
esmated), 
≤ MABEL Concentraon/AUC ÷ 100 or < Therapeuc 
concentraon/AUC  ÷ 10'000 (if seminal concentraon is 
measured)
2. EFD NOAEL available: 
Female AUC extrapolated from vaginal dose (male Cmax x 6 mL of 
semen) is any of the following:
≤ NOAEL-AUC ÷ 300 (if seminal concentraon is esmated) 
≤ NOAEL-AUC  ÷ 100 (If seminal concentraon is measured)
No male contracepve measures required 
Posive Genotoxicity: 
 Condom use (including duraon) as above for genotoxicity
Negave Genotoxicity: 
Condom use during treatment and up to end of relevant exposure 
in the exposed male or for 5 terminal half-lives 
Note: For teratogenic small molecules where condom use is 
required, this requirement applies to reproducvely competent 
men as well as to vasectomized men unless acve measurements 
fail to detect the molecule in seminal fluid. Furthermore, exposed 
men should agree to refrain from donang sperm. 
Negave Genotoxicity Tesng
Teratogenicity Tesng
No male contracepve measures for genotoxicity
Is the molecule first in class?
OR
Has the class/target of the molecule shown to be teratogenic in at least 1 of the following: Humans, EFD studies, transgenic models?
No
No proacve collecon of pregnancy informaon for female partner of 
exposed males
Yes
Proacve collecon of pregnancy informaon for female partner of 
exposed males
Genotoxicity Tesng 
EXPOSED MALES WITH PREGNANT PARTNER OR FEMALE PARTNER OF CHILD-BEARING POTENTIAL WITH UNKNOWN EARLY PREGNANCY STATUS 
EXPOSED MALES WITH NON-PREGNANT FEMALE PARTNER OF CHILD-BEARING POTENTIAL
Proacve collecon of pregnancy informaon for female partner of 
exposed males
Fig. 3 Algorithm for small molecules. ADI acceptable daily intake, AUC area under the curve, Cmax maximum concentration, EFD embryo-fetal devel-
opment, MABEL minimum anticipated biological effect level, NOAEL no adverse effect level, PDE permissible daily exposure
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1. No EFD studies available OR no EFD NOAEL  
Male Cmax/AUC is any of the following:
> Therapeuc concentraon/AUC x 500
> MABEL concentraon/AUC x 50,000
2. EFD NOAEL available:
Male AUC  is: 
> NOAEL-AUC x 5,000 
1. No EFD studies available OR no EFD NOAEL 
Male Cmax /AUC is any of the following:
≤  Therapeuc concentraon/AUC x 500
≤ MABEL concentraon/AUC x 50,000
2. EFD NOAEL available: 
Male AUC  is: 
≤ NOAEL-AUC x 5,000
No male contracepve measures requiredCondom use during treatment and up to end of 
relevant exposure in the exposed male or by default 
2 terminal half-lives
Note: For teratogenic mAbs where condom use is 
required, this requirement applies to reproducvely 
competent men as well as to vasectomized men 
unless acve measurements fail to detect the 
molecule in seminal fluid. Furthermore, exposed men 
should agree to refrain from donang sperm. 
Teratogenicity Tesng
Is the molecule first in class?
OR
Has the class/target of the molecule shown to be teratogenic in at least 1 of the following: Humans, EFD studies, 
transgenic models?
No
No proacve collecon of pregnancy informaon for 
female partner of exposed males
Yes
Proacve collecon of pregnancy informaon for 
female partner of exposed males
Genotoxicity Tesng not required
EXPOSED MALES WITH PREGNANT PARTNER OR FEMALE PARTNER OF CHILD-BEARING POTENTIAL WITH 
UNKNOWN EARLY PREGNANCY STATUS 
Fig. 4 Algorithm for monoclonal antibodies. AUC area under the curve, Cmax maximum concentration, EFD embryo-fetal development, mAb mono-
clonal antibody, MABEL minimum anticipated biological effect level, NOAEL no adverse effect level
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